- Home
- CRTO vs PTGX Comparison
CRTO vs PTGX Comparison
Compare CRTO & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRTO
- PTGX
- Stock Information
- Founded
- CRTO 2005
- PTGX 2006
- Country
- CRTO France
- PTGX United States
- Employees
- CRTO N/A
- PTGX N/A
- Industry
- CRTO Advertising
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- CRTO Consumer Discretionary
- PTGX Health Care
- Exchange
- CRTO Nasdaq
- PTGX Nasdaq
- Market Cap
- CRTO 1.4B
- PTGX 3.3B
- IPO Year
- CRTO 2013
- PTGX 2016
- Fundamental
- Price
- CRTO $23.71
- PTGX $55.01
- Analyst Decision
- CRTO Buy
- PTGX Strong Buy
- Analyst Count
- CRTO 11
- PTGX 9
- Target Price
- CRTO $44.70
- PTGX $67.11
- AVG Volume (30 Days)
- CRTO 407.5K
- PTGX 949.2K
- Earning Date
- CRTO 07-31-2025
- PTGX 08-05-2025
- Dividend Yield
- CRTO N/A
- PTGX N/A
- EPS Growth
- CRTO 107.32
- PTGX N/A
- EPS
- CRTO 2.44
- PTGX 0.86
- Revenue
- CRTO $1,934,668,000.00
- PTGX $207,801,000.00
- Revenue This Year
- CRTO N/A
- PTGX N/A
- Revenue Next Year
- CRTO $1.96
- PTGX $53.09
- P/E Ratio
- CRTO $9.71
- PTGX $61.45
- Revenue Growth
- CRTO N/A
- PTGX N/A
- 52 Week Low
- CRTO $23.24
- PTGX $32.50
- 52 Week High
- CRTO $49.93
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- CRTO 38.43
- PTGX 55.72
- Support Level
- CRTO $23.70
- PTGX $49.38
- Resistance Level
- CRTO $25.37
- PTGX $51.51
- Average True Range (ATR)
- CRTO 0.70
- PTGX 1.99
- MACD
- CRTO 0.18
- PTGX -0.25
- Stochastic Oscillator
- CRTO 33.33
- PTGX 52.31
About CRTO Criteo S.A.
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.